Hypera (OTCMKTS:HYPMY) Announces Quarterly Earnings Results

Hypera (OTCMKTS:HYPMY) announced its quarterly earnings results on Thursday. The company reported $0.02 earnings per share (EPS) for the quarter, Zacks reports. Hypera had a return on equity of 13.18% and a net margin of 20.04%. The company had revenue of $258.56 million during the quarter.

Hypera Price Performance

HYPMY opened at $3.62 on Friday. The firm has a fifty day moving average price of $3.27 and a 200 day moving average price of $3.74. Hypera has a 1 year low of $2.64 and a 1 year high of $6.90. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.68.

About Hypera

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.